DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/679f043a/drugeluting_stent) has announced the addition of the "Drug-eluting Stent Market in China 2011-2015" report to their offering.
TechNavio's analysts forecast the Drug-eluting Stent market in China to grow at a CAGR of 25.5 percent over the period 2011-2015. One of the key factors contributing to this market growth is the rising incidence of cardiovascular diseases in the country. The Drug-eluting Stent market in China has also been witnessing the trend of rise of medical tourism. However, price-cuts of Drug-eluting stents could pose a challenge to the growth of this market.
Key vendors dominating this market space include MicroPort Scientific Corp., Lepu Medical Technology Co. Ltd., Shandong JW Medical Products Co. Ltd., Abbott Vascular, and Medtronic Inc.
Commenting on the report, an analyst from TechNavio's Healthcare team said, IC procedures that are performed using DES are quite expensive. Hence, to reduce the cost of DESs to more affordable levels, the government of China and a few private players are offering reimbursements for IC procedures that are performed using DESs. However, it has been observed that stents that are imported from global healthcare vendors are either excluded from such medical insurance coverage schemes, or are only eligible for a very low percentage as reimbursement. In contrast, approximately 50-70 percent of the treatment cost is reimbursed in the case of treatments where regionally manufactured stents are used.
According to the report, in the Healthcare sector, there are numerous litigations and intellectual property rights issues among vendors, especially medical device manufacturers. Thus, DES vendors form strategic alliances to share their core competencies, as a result of which they can help develop innovative products in an effort to avoid litigation.
For more information visit http://www.researchandmarkets.com/research/679f043a/drugeluting_stent